Compounds > artemether
Page last updated: 2024-08-25

artemether and lopinavir

artemether has been researched along with lopinavir in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Aweeka, FT; Charlebois, E; Dorsey, G; German, P; Hanpithakpong, W; Havlir, D; Lawrence, J; Lindegardh, N; Parikh, S; Rosenthal, PJ1
Abiodun, OO; Akinbo, J; Ojurongbe, O1
Barnes, KI; Cohen, K; Kredo, T; Maartens, G; Mauff, K; Smith, PJ; Van der Walt, JS; Wiesner, L; Workman, L1
Aweeka, F; Ehrlich, H; Freeman, T; French, J; Goodwin, J; Huang, L; Kajubi, R; Kay, K; Li, F; Mwebaza, N; Ou, J; Parikh, S; Riggs, M; Ruiz-Garcia, A; Wade, M; Wang, K1

Trials

1 trial(s) available for artemether and lopinavir

ArticleYear
The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.
    BMC infectious diseases, 2016, Jan-27, Volume: 16

    Topics: Adult; Anti-HIV Agents; Artemether; Artemisinins; Drug Interactions; Ethanolamines; Female; Fluorenes; HIV Infections; HIV-1; Humans; Lopinavir; Lumefantrine; Male; Ritonavir

2016

Other Studies

4 other study(ies) available for artemether and lopinavir

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
    Journal of acquired immune deficiency syndromes (1999), 2009, Aug-01, Volume: 51, Issue:4

    Topics: Adult; Antimalarials; Area Under Curve; Artemether; Artemisinins; Cytochrome P-450 CYP3A; Drug Interactions; Ethanolamines; Female; Fluorenes; HIV Protease Inhibitors; Humans; Lopinavir; Lumefantrine; Male; Middle Aged; Pyrimidinones; Ritonavir

2009
The effect of lopinavir/ritonavir on the antimalarial activity of artemether or artemether/lumefantrine in a mouse model of Plasmodium berghei.
    Journal of chemotherapy (Florence, Italy), 2015, Volume: 27, Issue:1

    Topics: Animals; Anti-Retroviral Agents; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Coinfection; Disease Models, Animal; Drug Combinations; Drug Interactions; Ethanolamines; Fluorenes; HIV Infections; Lopinavir; Malaria; Mice; Plasmodium berghei; Ritonavir

2015
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
    Clinical pharmacology and therapeutics, 2023, Volume: 113, Issue:3

    Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Combinations; Fluorenes; HIV Infections; Humans; Lopinavir; Lumefantrine; Malaria; Malaria, Falciparum; Nevirapine; Ritonavir; Uganda

2023